Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Do not switch solvents based on forum anecdotes follow the supplier's reconstitution note
Which Medication Is Right for You
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
March 2026: Novo Nordisk reported top-line REDEFINE-1 Phase 3 CagriSema data showing 22.7% mean body weight reduction at 52 weeks , demonstrating superiority over standalone semaglutide 2.4mg and confirming the semaglutide-plus-amylin combination as clinically competitive with tirzepatide
If bubbles are present, gently tap the syringe and push them out before refilling
Always use the peptide calculator to verify before drawing
US$ 27.57
US$ 29.50
US$ 25.27
